SWOG clinical trial number
S0307A
Long-Term Bone Quality in Women With Breast Cancer (A Companion Study to S0307)
Closed
Phase
Accrual
0%
Abbreviated Title
ANCILLARY: S0307 Companion Study
Activated
10/01/2008
Closed
02/01/2010
Participants
Limited: Institutions Listed on the Title Page
Research committees
Breast Cancer
Eligibility Criteria Expand/Collapse
--Must provide consent to be enrolled in S0307;
--Must not have rickets, osteogenesis imperfecta, or osteosclerosis or osteomalacia;
--Must not have used prednisone prior to the diagnosis of breast cancer and within the last 10 years at a dose above 5 mg/day for 3 months or longer;
--Must not be using anticonvulsant medication;
--Must not have hyperparathyroidism;
--Patients must not have had a bone fracture since they were 21 years old unless it was caused by trauma;
--Must not have anorexia nervosa, currently or in the past, as diagnosed by a physician and serious enough to have caused abnormal menstruation;
--Must weigh less than 300 oounds;
--Must not have received any prior bisphosphonate therapy;
--Must not have a history of hypersensitivity to tetracycline or democlocycline.
--Must not have rickets, osteogenesis imperfecta, or osteosclerosis or osteomalacia;
--Must not have used prednisone prior to the diagnosis of breast cancer and within the last 10 years at a dose above 5 mg/day for 3 months or longer;
--Must not be using anticonvulsant medication;
--Must not have hyperparathyroidism;
--Patients must not have had a bone fracture since they were 21 years old unless it was caused by trauma;
--Must not have anorexia nervosa, currently or in the past, as diagnosed by a physician and serious enough to have caused abnormal menstruation;
--Must weigh less than 300 oounds;
--Must not have received any prior bisphosphonate therapy;
--Must not have a history of hypersensitivity to tetracycline or democlocycline.
Other Clinical Trials
SWOG Clinical Trial Number
S2206
A Randomized trial of neoadjuvant durvalumab plus chemotherapy versus chemotherapy alone for Adults with MammaPrint Ultrahigh (MP2) hormone receptor (HR) positive /Human Epidermal Growth Factor receptor (HER2) negative stage II-III breast cancer
Research Committee(s)
Breast Cancer
Symptom Control and Quality of Life
Activated
10/30/2023
Accrual
9%
Open
Phase
SWOG Clinical Trial Number
S2212
TIL Adapted Neo adjuvant Chemotherapy Optimization in Triple negative breast cancer (SCARLET)
Research Committee(s)
Breast Cancer
Activated
07/21/2023
Accrual
16%
Open
Phase
SWOG Clinical Trial Number
CTSU/NRG-BR007
A Phase III Clinical Trial Evaluating De-escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score </= 18 Breast Cancer
Research Committee(s)
Breast Cancer
Activated
06/07/2021
Open
Phase